Patent Grant
10966429
The present application relates to methods for using benzoxaborole compounds with preservative gases, such as carbon dioxide or sulfur dioxide, as an antimicrobial to control or inhibit pathogens of agricultural crops.
Benzoxaborole is a drug known to be effective in treating eukaryotic fungal and parasitic infections. For example, benzoxaborole is used to treat fungal conditions affecting the toenails and fingernails of humans, such as Onychomycosis. Benzoxaborole is also known to be an effective treatment of Human African Trypanosomiasis, commonly called African Sleeping Sickness, which is caused by T. brucei parasites that infect thousands of people annually in sub-Saharan Africa.
One mechanism by which benzoxaborole has been shown to exhibit antimicrobial effects is by blocking or inhibiting protein synthesis in fungi. Benzoxaborole has also been shown to block fungal cytoplasmic leucyl-tRNA synthetase (LeuRS) to exhibit antimicrobial effects. Additional mechanisms of action by which benzoxaborole acts as an antibacterial, an antifungal, or an antimicrobial are not yet understood.
Benzoxaborole has also been shown to have antimicrobial effects in plants. For example, a benzoxaborole compound was proven to be effective as a volatile plant fungicide. The present disclosure describes methods of using benzoxaborole compounds combined with preservative gases, such as carbon dioxide (CO2) and sulfur dioxide (SO2), to inhibit plant pathogens. More specifically, the present disclosure provides methods of using benzoxaboroles combined with CO2 or SO2 to provide synergistic antimicrobial protection to plants and plant parts that is advantageous to other previously described antimicrobial treatments of plants.
The present disclosure provides a method of treating plants with an antimicrobial agent. The method comprises placing one or more plants in a chamber, and sealing the chamber. The method also comprises adding a benzoxaborole compound to the sealed chamber. The method further comprises adding a preservative gas to the sealed chamber, wherein the benzoxaborole compound and the preservative gas combine in the chamber to form a treatment. Finally, the method provides for administering the treatment to the plants, and then, unsealing the chamber.
In the method described herein, the one or more plants may be a strawberry or a grape. In addition, the benzoxaborole compound of the present method may be Compound A, Compound B, and/or Compound C. Finally, in the present method of treating plants, the preservative gas may be CO2. All embodiments, features, elements, or limitations of the methods described herein are combinable with other embodiments, features, elements, or limitations of the methods described herein.
The following numbered embodiments are contemplated and are non-limiting:
1. A method of treating plants with an antimicrobial agent comprising:
2. The method of clause 1 or clause 2, wherein the one or more plants or plant parts is a soft fruit.
3. The method of clause 1, wherein the preservative gas is CO2 or SO2.
4. The method of clause 2 or clause 3, wherein the soft fruit is selected from the group consisting of a strawberry, a raspberry, a blackberry, and a grape.
5. The method of any one of clauses 1 to 4, wherein the benzoxaborole compound is selected from the group consisting of Compound A, Compound B, Compound C, and combinations thereof.
6. The method of any one of clauses 1 to 5, wherein the benzoxaborole compound is Compound A having the structure:
or an analog or a derivative thereof.
7. The method of any one of clauses 1 to 5, wherein the benzoxaborole compound is Compound B having the structure:
or an analog or a derivative thereof.
8. The method of any one of clauses 1 to 5, wherein the benzoxaborole compound is Compound C having the structure:
or an analog or a derivative thereof.
9. The method of any one of clauses 1 to 8, wherein the benzoxaborole compound is in the form of a liquid, a gas, a fog, or a solid.
10. The method of clause 9, wherein the solid benzoxaborole compound is a powder.
11. The method of any one of clauses 1 to 10, wherein the preservative gas is CO2.
12. The method of any one of clauses 1 to 10, wherein the preservative gas is SO2.
13. The method of any one of clauses 1 to 11, wherein the CO2 concentration of the antimicrobial treatment ranges from about 4% to about 20%.
14. The method of any one of clauses 1 to 10 and 12, wherein the SO2 concentration of the antimicrobial treatment ranges from about 0.001% to about 1%.
15. The method of any one of clauses 1 to 11 and 13, wherein the CO2 concentration of the antimicrobial treatment is about 12%.
16. The method of any one of clauses 1 to 15, wherein the antimicrobial treatment is in the form of a spray, a mist, a gel, a thermal fog, a non-thermal fog, a dip, a drench, a vapor, a gas, or sublimation.
17. The method of any one of clauses 1 to 16, wherein administering the antimicrobial treatment comprises release of the antimicrobial treatment from a material selected from the group consisting of a sachet, a synthetic film, a natural film, a liner, a gas-releasing generator, a compressed gas cylinder, a non-compressed gas cylinder, a cylinder comprising dissolved Supercritical CO2, and a droplet inside a box.
18. The method of any one of clauses 1 to 17, wherein the antimicrobial treatment further comprises a component selected from the group consisting of 1-methylcylopropene, adjuvants, and pesticides.
19. The method of any one of clauses 1 to 18, wherein the antimicrobial treatment further comprises a treatment carrier.
20. The method of clause 19, wherein the treatment carrier comprises a liquid, a gas, a solution, a solvent, and a chemical.
21. The method of clause 19 or clause 20, wherein the treatment carrier is Supercritical CO2.
22. The method of clause 19 or clause 20, wherein the treatment carrier is selected from the group consisting of water, saline, a buffer, a solution, and a solvent.
23. The method of any one of clauses 1 to 22, wherein the antimicrobial treatment is effective against plant pathogens.
24. The method of clause 23, wherein the plant pathogens are fungal pathogens.
25. The method of clause 23 or clause 24, wherein the plant pathogens are selected from the group consisting of Acremonium spp., Albugo spp., Alternaria spp., Ascochyta spp., Aspergillus spp., Botryodiplodia spp., Botryospheria spp., Botrytis spp., Byssochlamys spp., Candida spp., Cephalosporium spp., Ceratocystis spp., Cercospora spp., Chalara spp., Cladosporium spp., Colletotrichum spp., Cryptosporiopsis spp., Cylindrocarpon spp., Debaryomyces spp., Diaporthe spp., Didymella spp., Diplodia spp., Dothiorella spp., Elsinoe spp., Fusarium spp., Geotrichum spp., Gloeosporium spp., Glomerella spp., Helminthosporium spp., Khuskia spp., Lasiodiplodia spp., Macrophoma spp., Macrophomina spp., Microdochium spp., Monilinia spp., Monilochaethes spp., Mucor spp., Mycocentrospora spp., Mycosphaerella spp., Nectria spp., Neofabraea spp., Nigrospora spp., Penicillium spp., Peronophythora spp., Peronospora spp., Pestalotiopsis spp., Pezicula spp., Phacidiopycnis spp., Phoma spp., Phomopsis spp., Phyllosticta spp., Phytophthora spp., Polyscytalum spp., Pseudocercospora spp., Pyricularia spp., Pythium spp., Rhizoctonia spp., Rhizopus spp., Sclerotium spp., Sclerotinia spp., Septoria spp., Sphaceloma spp., Sphaeropsis spp., Stemphyllium spp., Stilbella spp., Thielaviopsis spp., Thyronectria spp., Trachysphaera spp., Uromyces spp., Ustilago spp., Venturia spp., and Verticillium spp., and bacterial pathogens, such as Bacillus spp., Campylobacter spp., Clavibacter spp., Clostridium spp., Erwinia spp., Escherichia spp., Lactobacillus spp., Leuconostoc spp., Listeria spp., Pantoea spp., Pectobacterium spp., Pseudomonas spp., Ralstonia spp., Salmonella spp., Shigella spp., Staphylococcus spp., Vibrio spp., Xanthomonas spp., and Yersinia spp.
26. The method of any one of clauses 23 to 25, wherein the plant pathogens are selected from the group consisting of Botrytis cinerea, Mucor piriformis, Fusarium sambucinum, Aspergillus brasiliensis, and Peniciliium expansum.
27. The method of any one of clauses 1 to 26, wherein the chamber is sealed.
28. The method of any one of clauses 1 to 27, wherein the temperature of the chamber ranges from 1° C. to 25° C.
29. The method of any one of clauses 1 to 28, wherein the chamber is air-tight.
30. The method of any one of clauses 1 to 29, wherein the chamber is semipermeable or impermeable.
31. The method of any one of clauses 1 to 30, wherein the chamber is made of a material selected from the group consisting of plastic, glass, cellulosic material, and cement.
32. The method of any one of clauses 1 to 31, wherein the chamber comprises a port, an outlet, or both.
33. The method of any one of clauses 1 to 32, wherein the chamber may have a volume ranging from about 10 L to about 50 L.
34. The method of any one of clauses 1 to 32, wherein the chamber may have a volume ranging from about 0.5 cm3 to about 150 cm3.
35. The method of any one of clauses 1 to 32, wherein the chamber may have a volume ranging from about 100 cm3 to about 10,000 cm3.
36. The method of any one of clauses 1 to 35, wherein the one or more plants or plant parts are manually or robotically placed in the chamber.
37. The method of any one of clauses 1 to 36, wherein the one or more plants or plant parts are treated for an initial time period ranging from about 12 hours to about 5 days.
38. The method of any one of clauses 1 to 37, wherein the antimicrobial treatment concentration ranges from about 0.0001 mg/L to about 0.5 mg/L.
39. The method of any one of clauses 1 to 38, wherein the time to administer the antimicrobial treatment ranges from about 3 seconds to about 2 hours.
40. The method of any one of clauses 1 to 39, wherein the method results in synergistic inhibition of plant pathogens on the one or more treated plants or plant parts.
The term “plant(s)” and “plant parts” include, but are not limited to, plant cells and plant tissues, such as leaves, calli, stems, roots, fruits, vegetables, flowers or flower parts, pollen, egg cells, zygotes, seeds, cuttings, cell or tissue cultures, or any other part or product of a plant. A class of plants that may be used in the present invention is generally as broad as the class of higher and lower plants including, but not limited to, dicotyledonous plants, monocotyledonous plants, and all horticultural crops.
Horticultural crops, include, but are not limited to, vegetable crops, fruit crops, edible nuts, flowers and ornamental crops, nursery crops, aromatic crops, and medicinal crops. More specifically, horticultural crops of the present disclosure include, but are not limited to, fruits (e.g., grape, apple, pear, and persimmon) and berries (e.g., strawberries, blackberries, blueberries, and raspberries).
The phrase “preservative gases” refers to chemicals in their gaseous form that acts as a preservative of the plants and plant parts of the present invention. For example, the preservative gases of the present application help maintain the appearance, freshness, flavor, and prevents rotting of the plants and plant parts of the present invention. Exemplary preservative gases of the present invention include, but are not limited to carbon dioxide (CO2) and sulfur dioxide (SO2).
The phrase “Supercritical CO2” refers to a solvent wherein the fluid state of carbon dioxide (CO2) is held at or above its critical temperature and critical pressure. Typically, CO2 at or above its critical temperature and critical pressure can adopt properties that are between a gas and a liquid. More specifically, the CO2 may behave as a supercritical fluid at or above its critical temperature and critical pressure, such that the CO2 can fill a container like a gas, but has a density like a liquid.
Compounds and Components of the Present Methods
The methods of the present disclosure are directed to using benzoxaborole compounds in combination with preservative gases or chemicals as an antimicrobial to treat plants or plant pants. The methods of the present disclosure to treat plant or plant parts comprise, consist essentially of, or consist of benzoxaborole compounds.
Exemplary embodiments of the compounds of the present disclosure comprise Compounds A, B, and C, which may encompass diastereomers and enantiomers of the illustrative compounds. Enantiomers are defined as one of a pair of molecular entities which are mirror images of each other and non-superimposable. Diastereomers or diastereoisomers are defined as stereoisomers other than enantiomers. Diastereomers or diastereoisomers are stereoisomers not related as mirror images. Diastereoisomers are characterized by differences in physical properties.
One exemplary embodiment of a benzoxaborole compound of the present method is Compound A:
or an analog or derivative thereof. An additional illustrative embodiment of a benzoxaborole compound of the present method is Compound B:
or an analog or derivative thereof.
Another exemplary embodiment of a benzoxaborole compound of the present method is Compound C, which is a salt version of Compounds A and/or B:
or an analog or derivative thereof.
Compounds A, B, and/or C may be used individually or as a mixture or combination. The benzoxaborole compounds may also be used in combination with preservative gases or chemicals to form a benzoxaborole treatment. The benzoxaborole treatment provides antimicrobial protection to plants or plant parts when administered, applied, or exposed to plants or plant parts.
Benzoxaborole Compounds A, B, and/or C may be used in any form, including, but not limited to, a liquid, a solid (e.g., a powder), or a gaseous composition. In particular, the present method provides application of a benzoxaborole compound as, for example, a spray, a mist, a gel, a thermal and non-thermal fog, a dip or a drench, or via sublimation, a vapor, or a gas. Additional examples of benzoxaborole treatment administration include, but are not limited to, release from a sachet, a synthetic or natural film, a liner or other packaging materials, a gas-releasing generator, compressed or non-compressed gas cylinder, dissolved in Supercritical CO2 within a cylinder, a droplet inside a box, or other similar methods as described in U.S. Pat. Nos. 8,669,207, 9,138,001, and 9,138,001, and U.S. Patent Publication No. 2014/0349853, which are incorporated herein by reference.
The active compounds may be applied to plants or plant parts in a volume of a chamber. A chamber of the present disclosure may be any sealable container from which a gas or chemical cannot easily escape once it has been introduced to the sealed chamber. For example, a chamber may be made of plastic, glass, or any other semipermeable or impermeable material.
The chamber may have a port (e.g., a bulkhead septum port) for the introduction of the chemical treatment, either as a gas or liquid (e.g., water or solvent-based solution containing the product) or a fog. The chamber may also have an outlet to vent or remove the unused portion of the treatment carrier.
Carriers of the present disclosure may be combined with active benzoxaborole compounds to form a benzoxaborole treatment. Treatment carriers of the present disclosure may comprise gases, solutions, solvents, or chemicals. For example, a liquid carrier of the present disclosure may comprise water, buffer, saline solution, a solvent, etc. Illustrative gas carriers for the present invention are Supercritical CO2 and/or CO2 contained in a steel cylinder.
A chamber of the present disclosure may be any container or material from which a gas or chemical can be introduced to a food product in the chamber. For example, a chamber may be made of plastic, glass, cellulosic material, cement, or any other semipermeable or impermeable material.
The chamber may be of any size that is large enough to hold plants and plant parts to be treated. For example, an exemplary chamber may have a volume of about 10 liters (L) to about 50 L, from about 20 L to about 40 L, from about 25 L to about 50 L, from about 30 L to about 40 L, from about 35 L to about 40 L, and at about 35 L or about 36 L. In addition, an illustrative chamber may be a pallet that may have a size, sealed or unsealed ranging from 0.5 cubic meters to about 150 cubic meters.
In addition, an exemplary chamber of the present invention may be a large storage room (e.g., a gymnasium) having a headspace of several hundred to several thousand cubic meters. Thus, an exemplary chamber of the present invention may have a headspace size ranging from 100 to about 10,000 cubic meters, from about 100 to about 8000 cubic meters, from about 100 to about 7500 cubic meters, from about 100 to about 5000 cubic meters, from about 200 to about 3000 cubic meters, and about 1000 cubic meters.
Gaseous benzoxaborole treatments may be applied to the plants or plants parts at a concentration that is applied over approximately 3 to about 5 seconds to about two hours. The gas chemical treatment concentration may be reported as the amount (milligrams, mg) of active ingredient (i.e., benzoxaborole compound) per volume (liter, L) of chamber headspace or amount (milligrams, mg) of active ingredient (i.e. benzoxaborole compound) per mass (kilogram, kg) of crop.
For example, the rate that the benzoxaborole treatment may be effectively applied in a chamber and/or to plants may range from 0.001 mg/L to 0.5 mg/L. For example, the rate of the benzoxaborole treatment may be from about 0.002 mg/L to about 0.2 mg/L, 0.002 mg/L to about 0.14 mg/L, 0.002 mg/L to about 0.035 mg/L, 0.002 mg/L to about 0.0088 mg/L, 0.002 mg/L to about 0.044 mg/L, from about 0.004 mg/L to about 0.15 mg/L, from about 0.0044 mg/L to about 0.14 mg/L, from about 0.0044 mg/L to about 0.0088 mg/L, from about 0.0044 mg/L to about 0.035 mg/L, from about 0.0088 mg/L to about 0.14 mg/L, from about 0.035 mg/L to about 0.14 mg/L, from about 0.0088 mg/L to about 0.035 mg/L, from about 0.001 mg/L to about 0.2 mg/L, from about 0.001 mg/L to about 0.14 mg/L, from about 0.001 mg/L to about 0.0088 mg/L, from about 0.001 mg/L to about 0.0044 mg/L, and at about 0.0044 mg/L, about 0.0088 mg/L, about 0.035 mg/L, and about 0.14 mg/L.
Exemplary preservative gases of the method described herein include, but are not limited to, carbon dioxide (CO2) and sulfur dioxide (SO2). Additional chemicals that may be combined with benzoxaborole compound in the present disclosure include, but are not limited to, 1-methylcyclopropene, adjuvant(s), and commercial pesticides. Further chemicals that may be used in the present method include some that have been federally recognized. For example, Food, Drug and Cosmetic Act §§201 and 409 Generally Recognized As Safe (GRAS) compounds and Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) §25(b) chemicals, including eugenol, clove, thyme or mint oils), natural compounds, or compounds derived from natural sources may also be used in the present method.
While any concentration of preservative gas or chemical that provides the antimicrobial effect described herein may be utilized, a percent of CO2 gas or chemical that may be used in the present method includes, but is not limited to, from about 4% to about 20%, from about 5% to about 18%, from about 6% to about 17%, from about 7% to about 15%, from about 8% to about 14%, from about 8% to about 13%, from about 8% to about 12%, from about 5% to about 14%, from about 6% to about 13%, from about 7% to about 13%, and at about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, and about 14%.
A percent of SO2 gas or chemical that may be used in the present method includes, but is not limited to, from about 0.001% to about 1%, from about 0.005% to about 1%, from about 0.01% to about 1%, from about 0.05% to about 1%, and from about 0.1% to about 1%.
Any plants or plant parts, plant cells, or plant tissues may be treated using the present method. A class of plants that may be treated in the present invention is generally as broad as horticultural crops. Horticultural crops, include, but are not limited to, vegetable crops, fruit crops, edible nuts, flowers and ornamental crops, nursery crops, aromatic crops, and medicinal crops. More specifically, fruits (e.g., grape, apple, pear, and persimmon) and berries (e.g., strawberries, blackberries, blueberries, and raspberries) are plants encompassed by the present disclosure. It should be noted that any species of berries or fruits may be used in the present invention (e.g., Table grapes).
Plants and agricultural crops after harvest may be used in the method of the present application. For example, exemplary plants of the present invention include post-harvest plants and crops during field packing, palletization, in-box, during storage, and throughout the distribution network. Further, plants being transported by any mode, including, but not limited to local vehicles, transport trailers, marine containers, aircraft containers, etc. may be treated using the method described herein. For example, minimally-processed packaged products (e.g., packaged vegetables or fruits) may also be treated with the method described herein.
Methods of Using Benzoxaborole Compounds
The present disclosure is directed to methods of providing antimicrobial protection to plants from plant pathogens. More specifically, fungal plant pathogens may be treated, prevented, or eradicated by the method described herein. Exemplary, pathogens encompassed by the present disclosure include, but are not limited to, Botrytis cinerea, Mucor piriformis, Fusarium sambucinum, Aspergillus brasiliensis, and Peniciliium expansum. Additional pathogens encompassed by the present invention include, but are not limited to Acremonium spp., Albugo spp., Alternaria spp., Ascochyta spp., Aspergillus spp., Botryodiplodia spp., Botryospheria spp., Botrytis spp., Byssochlamys spp., Candida spp., Cephalosporium spp., Ceratocystis spp., Cercospora spp., Chalara spp., Cladosporium spp., Colletotrichum spp., Cryptosporiopsis spp., Cylindrocarpon spp., Debaryomyces spp., Diaporthe spp., Didymella spp., Diplodia spp., Dothiorella spp., Elsinoe spp., Fusarium spp., Geotrichum spp., Gloeosporium spp., Glomerella spp., Helminthosporium spp., Khuskia spp., Lasiodiplodia spp., Macrophoma spp., Macrophomina spp., Microdochium spp., Monilinia spp., Monilochaethes spp., Mucor spp., Mycocentrospora spp., Mycosphaerella spp., Nectria spp., Neofabraea spp., Nigrospora spp., Penicillium spp., Peronophythora spp., Peronospora spp., Pestalotiopsis spp., Pezicula spp., Phacidiopycnis spp., Phoma spp., Phomopsis spp., Phyllosticta spp., Phytophthora spp., Polyscytalum spp., Pseudocercospora spp., Pyricularia spp., Pythium spp., Rhizoctonia spp., Rhizopus spp., Sclerotium spp., Sclerotinia spp., Septoria spp., Sphaceloma spp., Sphaeropsis spp., Stemphyllium spp., Stilbella spp., Thielaviopsis spp., Thyronectria spp., Trachysphaera spp., Uromyces spp., Ustilago spp., Venturia spp., and Verticillium spp., and bacterial pathogens, such as Bacillus spp., Campylobacter spp., Clavibacter spp., Clostridium spp., Erwinia spp., Escherichia spp., Lactobacillus spp., Leuconostoc spp., Listeria spp., Pantoea spp., Pectobacterium spp., Pseudomonas spp., Ralstonia spp., Salmonella spp., Shigella spp., Staphylococcus spp., Vibrio spp., Xanthomonas spp., and Yersinia spp.
The benzoxaborole and preservative gas treatments may be applied to the plants or plants parts inside of a container or chamber. The chamber may be open or closed/sealed during application of the benzoxaborole and preservative gas treatment. Typically, the plants or plant parts are manually or robotically placed in the chamber, and the chamber is then sealed. The benzoxaborole and preservative gas treatment is then applied to the sealed chamber comprising the plants or plant parts via the port (e.g., a bulkhead septum port).
The benzoxaborole and preservative gas treatments are applied to the sealed chamber for an initial time period. For example, the plants may be exposed to the treatments in the chamber or sealed container for any initial time period. An illustrative initial time period may range from about 12 hours to about 5 days (120 hours), from about 1 day to about 4 days, from about 2 days to about 3.5 days, from about 2 days to about 3.5 days, and at about 3.5 days. The temperature of the sealed chamber can range from about 1° C. to about 25° C.
After expiration of the treatment time period, inhibition of plant pathogens may be assessed. For example, in vitro samples may have the growth of the pathogen on agar or in media assessed, evaluated, and compared to a control sample where no benzoxaborole or preservative gas treatment was administered or different treatment conditions were applied. Similarly, in vivo samples may have the severity and incidence of fungal or bacterial disease assessed, evaluated, and compared to a control sample where no benzoxaborole or preservative gas treatment was administered or different treatment conditions were applied.
Synergy of benzoxaborole compounds combined with a gas and/or a chemical to form a benzoxaborole treatment was determined using the Colby equation, E=x+y−x*y/100, where:
Illustrative embodiments of the methods of the present disclosure are provided herein by way of examples. While the concepts and technology of the present disclosure are susceptible to broad application, various modifications, and alternative forms, specific embodiments will be described here in detail. It should be understood, however, that there is no intent to limit the concepts of the present disclosure to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives consistent with the present disclosure and the appended claims.
The following experiments were used to determine synergy between benzoxaborole Compounds A, B, and/or C and preservative gases, such as carbon dioxide (CO2) and sulfur dioxide (SO2). Specific rates or any other unique conditions are noted within the corresponding results tables. Each experiment comprised an air-tight 36 liter (L) chamber (Fisher Scientific, P/N: 08-642-23C), fitted with a bulkhead septum port (Swagelok, P/N: SS-400-61, Solon, Ohio) used for treatment delivery, as well as for monitoring (using needle extraction) carbon dioxide (CO2), sulfur dioxide (SO2), oxygen (O2) or other headspace samples. A variable speed fan (Thermaltake, Mobile Fan II, P/N: A1888, Taipei City, Taiwan) set to low was also used to circulate the headspace atmosphere.
In Vitro and In Vivo Experiments
In vitro and in vivo experiments were performed concurrently in triple replicates (i.e., triplicate) unless otherwise noted. For in vitro experiments, a single 6-well microtiter plate or three, 10-cm petri plates each containing half strength Potato Dextrose Agar were prepared. Each well or plate was inoculated with 1 microliter (μL) of 1×105 spores/ml of the appropriate pathogenic spore suspension (e.g., Botrytis cinerea, BOTRCI; Penicillium expansum, PENIEX; Mucor piriformis, MUCOPI; Fusarium sambucinum FUSASA; or Aspergillus brasiliensis, ASPEBR). The inoculated microtiter or petri plates were then sealed with a breathable film (AeraSeal; P/N: B-100, Excel Scientific, Victorville, Calif.).
For in vivo experiments, eight strawberry fruits per repetition were surface sterilized with a 70% ethanol solution. After sterilization, the strawberries were rinsed twice with deionized water. Each strawberry fruit was wounded using a T15 screwdriver tip to a uniform depth of eight mm (8 mm). Each fruit wound was inoculated with 20 μL of 1×105 spores/ml pathogen spore suspension of B. cinerea or M. piriformis. The strawberries were then placed with the stem facing downwards inside a 1-pound strawberry clamshell.
Similarly, table grape fruits were also tested in vivo. More specifically, 16-20 table grapes per repetition were washed and inoculated with pathogens (as described above for the strawberries). However, an ethanol-sterilized push pin, rather than a T15 screwdriver, was used to wound the stem-end of the grapes. The grapes were inoculated in the wound, and then arranged inside a 1-pint clamshell.
For treatment, the inoculated agar plates and clamshells containing fruits (e.g., strawberries and grapes) were placed inside a 36 L experimental chamber unit, which was then sealed prior to commencement of compound treatments. The chamber remained sealed throughout the duration of the experiment except for addition of treatment to the chamber, and post-treatment ventilation.
Benzoxaborole Compound and Preservative Gas Treatment of Agar Plates (In Vitro) and Fruits
Benzoxaborole Compound A or Compound B was dissolved in acetone and dispensed onto a 60 mm Whatman #1 filter paper disk using a pipette. The acetone was permitted to evaporate for five minutes before the disk was placed on a watch glass in each chamber.
A 12% CO2 headspace treatment was then established in the chamber by permitting 10 grams (g) of crushed dry ice placed in a weigh boat in the chamber to evaporate in the sealed chamber. However, the bulkhead port of the chamber was loosened to permit the release of internal pressure. Optionally, a fan was used during the initial hours of treatment (i.e., up to about 6 hours of treatment) to ensure uniform treatment exposure of fruits and plates.
Untreated controls and CO2 treated chambers contained an acetone-treated disk with similar evaporation for five minutes. CO2 and O2 levels in the chamber were monitored using a handheld gas detector (Dansensor Checkpoint II; P/N 600111, Ringsted, Denmark). Temperature and relative humidity were also monitored within the chamber using data loggers (Onset HOBO; P/N U12-013, Bourne, Mass.).
The chamber for all in vitro and in vivo experiments was held at room temperature (i.e., from about 21° C. to about 23° C.) typically for about 3.5 days (i.e., about 84 hours) of treatment exposure. Chambers were then vented. After an additional 2-3 days with the chamber at room temperature, post-treatment radial growth (in mm) of each in vitro pathogen (see Examples 1-7, Tables 1-7) was measured on the inoculated plates using electronic calipers (Mitutoyo, P/N: CD-6-CX, Aurora, Ill.). In addition, the point of inoculation on fruits was assessed for indication of in vivo disease incidence (e.g., yes or no) and severity of disease incidence (see Examples 8-16, Tables 8-16). Disease severity was rated on a scale ranging from 0 to 4, where “0” indicated no disease severity, “1” indicated minimal disease severity, “2” indicated medium disease severity, “3” indicated high disease severity, and “4” indicated exceptionally high disease severity.
Synergy was determined using the following Colby equation,
E=x+y−x*y/100, where:
Table 1 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on agar plates. As expected, the plates treated with the control (i.e., air) showed the highest pathogenic growth of 34 mm of BOTRCI and 22.6 mm of PENIEX. Methods of treating plant pathogens were used on agar plates growing BOTRCI and PENIEX and treated with 12% CO2 only had 28 mm and 18.6 mm of pathogenic growth, respectively. Plates growing BOTRCI and PENIEX and treated with 0.14 mg/L of benzoxaborole Compound A only had 16.3 mm and 17 mm of pathogenic growth, respectively. However, the plates treated with both benzoxaborole Compound A and 12% CO2 showed no growth and 3.3 mm of growth for BOTRCI and PENIEX pathogens, respectively. The Colby calculations of 165.4 and 225 indicated that the benzoxaborole treatment of Compound A and CO2 was synergistic over the other treatments to inhibit BOTRCI and PENIEX in vitro growth, respectively.
Botrytis cinerea (BOTRCI) and Penicillium expansum (PENIEX) when evaluated 2 days after
aAssay was performed using a 6-well microtiter plate
bExperiment was performed with 4 replicates
cFan was used for first 6 hours of treatment
Table 2 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on agar plates. As expected, the plate treated with the control (i.e., air) showed the highest pathogenic growth of 24.6 mm of PENIEX. Methods of treating plant pathogens were used on agar plates growing PENIEX and treated with 12% CO2 only had 21.3 mm of pathogenic growth. Plates growing PENIEX and treated with 0.14 mg/L of benzoxaborole Compound A only had 9.7 mm of pathogenic growth. However, the plates treated with both benzoxaborole Compound A and 12% CO2 showed 5.2 mm of growth for PENIEX pathogens. The Colby calculation of 119.7 indicated that the benzoxaborole treatment with Compound A and CO2 was synergistic over the other treatments to inhibit PENIEX growth in vitro.
a Assay was performed using a 6-well microtiter plate
b Fan was used for first 6 hours of treatment
c Additional water vapor was added to each chamber to achieve >90% R.H.
Table 3 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on agar plates. As expected, the plate treated with the control (i.e., air) showed the highest pathogenic growth of 35 mm for both BOTRCI and MUCOPI. Methods of treating plant pathogens were used on agar plates growing BOTRCI and MUCOPI and treated with 12% CO2 only had 30.9 mm and 35 mm of pathogenic growth, respectively. Plates growing BOTRCI and MUCOPI and treated with 0.14 mg/L of benzoxaborole Compound A only had 5.5 mm and 22.3 mm of pathogenic growth, respectively. However, the plates treated with both benzoxaborole Compound A and 12% CO2 showed 4.5 mm and 11 mm of growth for BOTRCI and MUCOPI pathogens, respectively. The Colby calculations of 101.2 and 189 indicated that the benzoxaborole treatment of Compound A and CO2 was synergistic over the other treatments to inhibit BOTRCI and PENIEX in vitro growth, respectively.
a Assay was performed using a 6-well microtiter plate
b Fan was used for first 6 hours of treatment
c Additional water vapor was added to each chamber to achieve >90% R.H.
Table 4 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on agar plates. As expected, the plate treated with the control (i.e., air) showed the highest pathogenic growth of 35 mm of BOTRCI and 25.3 mm of PENIEX. Methods of treating plant pathogens were used on agar plates growing BOTRCI and PENIEX and treated with 12% CO2 only had 33.4 mm and 21.2 mm of pathogenic growth, respectively. Plates growing BOTRCI and PENIEX and treated with 0.14 mg/L of benzoxaborole Compound A only had 1.5 mm and 6.4 mm of pathogenic growth, respectively. However, the plates treated with both benzoxaborole Compound A and 12% CO2 showed no growth and 0.5 mm of growth for BOTRCI and PENIEX pathogens, respectively. The Colby calculations of 104.3 and 124.4, respectively, indicated that the benzoxaborole treatment of Compound A and CO2 was synergistic over the other treatments to inhibit BOTRCI and PENIEX growth in vitro.
a Assay was performed using a 6-well microtiter plate
b Fan was used for first 6 hours of treatment
Table 5 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on agar plates. As expected, the plate treated with the control (i.e., air) showed the highest pathogenic growth of 32.9 mm of BOTRCI, 22.7 mm of PENSIEX, 33.9 mm of FUSASA, and 29.6 mm of ASPEBR. Methods of treating plant pathogens were used on agar plates growing BOTRCI, PENIEX, FUSASA, and ASPEBR and treated with 12% CO2 only had 35 mm, 19.9 mm, 33.9 mm, and 26.2 mm of pathogenic growth, respectively. Plates growing BOTRCI, PENIEX, FUSASA, and ASPEBR and treated with 0.14 mg/L of benzoxaborole Compound A only had 3.6 mm, 10.2 mm, 5.0 mm, and 2.6 mm of pathogenic growth, respectively. However, the plates treated with both benzoxaborole Compound A and 12% CO2 showed 3 mm, 8.6 mm, 3.8 mm, and no growth of BOTRCI, PENIEX, FUSASA, and ASPEBR pathogens, respectively. The Colby calculations of 102.9, 102.5, 104.0, and 108.3 indicated that the benzoxaborole treatment of Compound A and CO2 was synergistic over the other treatments to inhibit BOTRCI, PENIEX, FUSASA, and ASPEBR in vitro growth, respectively.
Plates growing BOTRCI, PENIEX, FUSASA, and ASPEBR and treated with 0.14 mg/L of benzoxaborole Compound B only had 3.5 mm, 7.7 mm, 3.6 mm, and 3.6 mm of pathogenic growth, respectively. However, plates treated with both benzoxaborole Compound B and 12% CO2 showed 2.7 mmm, 6.4 mm, 3.4 mm, and no growth of BOTRCI, PENIEX, FUSASA, and ASPEBR pathogens, respectively. The Colby calculations of 103.4, 102.4, 100.4, and 112.0 indicated that the benzoxaborole treatment of Compound B and CO2 was synergistic over the other treatments to inhibit BOTRCI, PENIEX, FUSASA, and ASPEBR in vitro growth, respectively.
sambucinum (FUSASA), and Aspergillusbrasiliensis (ASPEBR) when evaluated 2 days
a Assay was performed using a 6-well microliter plate
b Fan was used for first 6 hours of treatment
c Additional water vapor was added to each chamber to achieve >90% R.H,
Table 6 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on agar plates. As expected, the plate treated with the control (i.e., air) showed the highest pathogenic growth of 85.0 mm of BOTRCI. Methods of treating plant pathogens were used on agar plates growing BOTRCI and treated with 12% CO2 only had 78.9 mm of pathogenic growth. Plates growing BOTRCI and treated with 0.14 mg/L of benzoxaborole Compound A only had 13.2 mm of pathogenic growth. However, the plates treated with both benzoxaborole Compound A and 12% CO2 showed 6.4 mm of growth for BOTRCI pathogens. The Colby calculation of 108.2 indicated that the benzoxaborole treatment with Compound A and CO2 was synergistic over the other treatments to inhibit BOTRCI growth in vitro.
a Assay was performed using a 10 cm petri plates
b Fan was run continuous during treatment
Table 7 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on agar plates. As expected, the plate treated with the control (i.e., air) showed the highest pathogenic growth of 32.8 mm of PENIEX. Methods of treating plant pathogens were used on agar plates growing PENIEX and treated with 12% CO2 only had 25.8 mm of pathogenic growth. Plates growing PENIEX and treated with benzoxaborole Compound A only had 10.6 mm of pathogenic growth. However, the plates treated with both benzoxaborole Compound A and 12% CO2 showed 4.7 mm of growth for PENIEX pathogens. The Colby calculation of 114.7 indicated that the benzoxaborole treatment with Compound A and CO2 was synergistic over the other treatments to inhibit PENIEX growth in vitro.
a Assay was performed using a 10 cm Petri plates
b Fan was run continuous during treatment
Table 8 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on fruit, such as strawberries. As expected, the fruit treated with the control (i.e., air) showed the highest pathogenic growth of 4.0 mm of BOTRCI. Methods of treating plant pathogens were used on fruit growing BOTRCI and treated with 12% CO2 only had 3.7 mm of pathogenic growth. Fruit growing BOTRCI and treated with 0.14 mg/L of benzoxaborole Compound A only had 2.1 mm of pathogenic growth. However, the fruit treated with both benzoxaborole Compound A and 12% CO2 only showed 0.4 mm of growth for BOTRCI pathogens. The Colby calculation of 176.2 indicated that the benzoxaborole treatment with Compound A and CO2 was synergistic over the other treatments to inhibit BOTRCI growth in vivo.
a Experiment was performed with 4 replicates
b Fan was used for first 6 hours of treatment
c Additional water vapor was added to each chamber to achieve >90% R.H.
Table 9 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on fruit, such as strawberries. As expected, the fruit treated with the control (i.e., air) showed the highest pathogenic growth of 3.8 mm of BOTRCI. Methods of treating plant pathogens were used on fruit growing BOTRCI and treated with 12% CO2 only had 3.5 mm of pathogenic growth. Fruit growing BOTRCI and treated with 0.14 mg/L of benzoxaborole Compound A only had 1.1 mm of pathogenic growth. However, the fruit treated with both benzoxaborole Compound A and 12% CO2 showed 0.8 mm of growth for BOTRCI pathogens. The Colby calculation of 107.6 indicated that the benzoxaborole treatment with Compound A and CO2 was synergistic over the other treatments to inhibit BOTRCI growth in vivo.
a Fan was used for first 6 hours of treatment
b Additional water vapor was added to each chamber to achieve >90% R H.
Table 10 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on fruit, such as strawberries. As expected, the fruit treated with the control (i.e., air) showed the highest pathogenic growth of 3.6 mm of MUCOPI. Methods of treating plant pathogens were used on fruit growing MUCOPI and treated with 12% CO2 only had 3.0 mm of pathogenic growth. Fruit growing MUCOPI and treated with 0.14 mg/L of benzoxaborole Compound A only had 0.5 mm of pathogenic growth. However, the fruit treated with both benzoxaborole Compound A and 12% CO2 showed 0.2 mm of growth for MUCOPI pathogens. The Colby calculation of 106.8 indicated that the benzoxaborole treatment with Compound A and CO2 was synergistic over the other treatments to inhibit MUCOPI growth in vivo.
a Fan was used for first 6 hours of treatment
b Additional water vapor was added to each chamber to achieve >90% R H.
Table 11 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on fruit, such as strawberries. As expected, the fruit treated with the control (i.e., air) showed the highest pathogenic growth of 3.7 mm of BOTRCI. Methods of treating plant pathogens were used on fruit growing BOTRCI and treated with 12% CO2 only had 2.7 mm of pathogenic growth. Fruit growing BOTRCI and treated with 0.14 mg/L of benzoxaborole Compound A only 1.4 mm of pathogenic growth. However, the fruit treated with both benzoxaborole Compound A and 12% CO2 showed 0.8 mm of growth for BOTRCI pathogens. The Colby calculation of 109.0 indicated that the benzoxaborole treatment with Compound A and CO2 was synergistic over the other treatments to inhibit BOTRCI growth in vivo.
Fruit growing BOTRCI and treated with benzoxaborole Compound B only had 0.9 mm of pathogenic growth. However, the fruit treated with both benzoxaborole Compound B and 12% CO2 showed 0.5 mm of growth for BOTRCI pathogens. The Colby calculation of 105.0 indicated that the benzoxaborole treatment with Compound B and CO2 was synergistic over the other treatments to inhibit BOTRCI growth in vivo.
a Fan was used for first 6 hours of treatment
b Additional water vapor was added to each chamber to achieve >90% R H.
Table 12 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on fruit, such as strawberries. As expected, the fruit treated with the control (i.e., air) showed the highest pathogenic growth of 3.6 mm of BOTRCI. Methods of treating plant pathogens were used on fruit growing BOTRCI and treated with 12% CO2 only had 3.4 mm of pathogenic growth. Fruit growing BOTRCI and treated with 0.14 mg/L of benzoxaborole Compound A only 0.7 mm of pathogenic growth. However, the fruit treated with both benzoxaborole Compound A and 12% CO2 showed 0.4 mm of growth for BOTRCI pathogens. The Colby calculation of 107.9 indicated that the benzoxaborole treatment with Compound A and CO2 was synergistic over the other treatments to inhibit BOTRCI growth in vivo.
Fruit growing BOTRCI and treated with benzoxaborole Compound B only had 0.4 mm of pathogenic growth. However, the fruit treated with both benzoxaborole Compound B and 12% CO2 showed 0.3 mm of growth for BOTRCI pathogens. The Colby calculation of 100.9 indicated that the benzoxaborole treatment with Compound B and CO2 was synergistic over the other treatments to inhibit BOTRCI growth in vivo.
a Fan was used for first 6 hours of treatment
b Additional water vapor was added to each chamber to achieve >90% R.H.
Table 13 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on fruit, such as strawberries. As expected, the fruit treated with the control (i.e., air) showed the highest pathogenic growth of 3.4 mm of BOTRCI. Methods of treating plant pathogens were used on fruit growing BOTRCI and treated with 12% CO2 only had 3.2 mm of pathogenic growth. Fruit growing BOTRCI and treated with 0.14 mg/L of benzoxaborole Compound A only had 2.4 mm of pathogenic growth. However, the fruit treated with both benzoxaborole Compound A and 12% CO2 only showed 1.4 mm of growth for BOTRCI pathogens. The Colby calculation of 163.4 indicated that the benzoxaborole treatment with Compound A and CO2 was synergistic over the other treatments to inhibit BOTRCI growth in vivo.
a Fan was run continuously during treatment
Table 14 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on fruit, such as strawberries. As expected, the fruit treated with the control (i.e., air) showed the highest pathogenic growth of 4.0 mm of BOTRCI. Methods of treating plant pathogens were used on fruit growing BOTRCI and treated with 12% CO2 only had 3.9 mm of pathogenic growth. Fruit growing BOTRCI and treated with 0.0044 mg/L or 0.0088 mg/L benzoxaborole Compound A only had 3.4 mm and 3.3 mm of pathogenic growth, respectively. However, the fruit treated with 0.0044 mg/L or 0.0088 mg/L of benzoxaborole Compound A and 12% CO2 only showed 3.2 mm and 0.6 mm of growth for BOTRCI pathogens, respectively. The Colby calculation of 114.8 and 502.5 indicated that the benzoxaborole treatment with 0.0044 mg/L or 0.0088 mg/L Compound A, respectively, combined with CO2 was synergistic over the other treatments to inhibit BOTRCI growth in vivo.
a Fan was run continuous during treatment
Table 15 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on fruit, such as Table grapes. As expected, the fruit treated with the control (i.e., air) showed the highest pathogenic growth of 1.6 mm of BOTRCI. Methods of treating plant pathogens were used on fruit growing BOTRCI and treated with 12% CO2 only had 1.4 mm of pathogenic growth. Fruit growing BOTRCI and treated with 0.035 mg/L of benzoxaborole Compound A only had 0.9 mm of pathogenic growth. However, the fruit treated with both benzoxaborole Compound A and 12% CO2 only showed 0.7 mm of growth for BOTRCI pathogens. The Colby calculation of 115.2 indicated that the benzoxaborole treatment with Compound A and CO2 was synergistic over the other treatments to inhibit BOTRCI growth in vivo.
a Fan was run continuous during treatment
Table 16 demonstrates that the present method may be used to inhibit growth of plant pathogens inoculated on fruit, such as Table grapes. As expected, the fruit treated with the control (i.e., air) showed the highest pathogenic growth of 2.4 mm of PENIEX. Methods of treating plant pathogens were used on fruit growing PENIEX and treated with 12% CO2 only had 1.9 mm of pathogenic growth. Fruit growing PENIEX and treated with 0.035 mg/L of benzoxaborole Compound A only had 1.8 mm of pathogenic growth. However, the fruit treated with both benzoxaborole Compound A and 12% CO2 only showed 1.3 mm of growth for PENIEX pathogens. The Colby calculation of 108.2 indicated that the benzoxaborole treatment with Compound A and CO2 was synergistic over the other treatments to inhibit PENIEX growth in vivo.
a Fan was run continuous during treatment
The preceding description enables others skilled in the art to utilize the technology in various embodiments and with various modifications as are suited to the particular use contemplated. In accordance with the provisions of the patent statutes, the principles and modes of operation of this disclosure have been explained and illustrated in exemplary embodiments. Accordingly, the present invention is not limited to the particular embodiments described and/or exemplified herein.
It is intended that the scope of disclosure of the present technology be defined by the following claims. However, it must be understood that this disclosure may be practiced otherwise than is specifically explained and illustrated without departing from its spirit or scope. It should be understood by those skilled in the art that various alternatives to the embodiments described herein may be employed in practicing the claims without departing from the spirit and scope as defined in the following claims.
The scope of this disclosure should be determined, not only with reference to the above description, but should instead be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. It is anticipated and intended that future developments will occur in the arts discussed herein, and that the disclosed compositions and methods will be incorporated into such future examples.
Furthermore, all terms used in the claims are intended to be given their broadest reasonable constructions and their ordinary meanings as understood by those skilled in the art unless an explicit indication to the contrary is made herein. In particular, use of the singular articles such as “a,” “the,” “said,” etc. should be read to recite one or more of the indicated elements unless a claim recites an explicit limitation to the contrary. It is intended that the following claims define the scope of the disclosure and that the technology within the scope of these claims and their equivalents be covered thereby. In sum, it should be understood that the disclosure is capable of modification and variation and is limited only by the following claims
This application claims the benefit under 35 USC § 119(e) of U.S. Provisional Patent Application Ser. No. 62/304,636, filed on Mar. 7, 2016, the entire disclosure of which is incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3686398 | Kohn et al. | Aug 1972 | A |
| 3873279 | Singer | Mar 1975 | A |
| 4421774 | Vidal et al. | Dec 1983 | A |
| 4843956 | Lashlee | Jul 1989 | A |
| 5880188 | Austin et al. | Mar 1999 | A |
| 5958463 | Milne | Sep 1999 | A |
| 6305148 | Bowden et al. | Oct 2001 | B1 |
| 7078546 | Piers | Jul 2006 | B2 |
| 7119049 | Rieck et al. | Oct 2006 | B2 |
| 7176228 | Elbe et al. | Feb 2007 | B2 |
| 7179840 | Rieck et al. | Feb 2007 | B2 |
| 7208169 | Dunkel et al. | Apr 2007 | B2 |
| 7390806 | Lee et al. | Jun 2008 | B2 |
| 7393856 | Bellinger-Kawahara et al. | Jul 2008 | B2 |
| 7465836 | Lee et al. | Dec 2008 | B2 |
| 7582621 | Baker et al. | Sep 2009 | B2 |
| 7652000 | Perry et al. | Jan 2010 | B2 |
| 7767657 | Baker et al. | Aug 2010 | B2 |
| 7816344 | Baker et al. | Oct 2010 | B2 |
| 7842823 | Chang et al. | Nov 2010 | B2 |
| 7888356 | Lee et al. | Feb 2011 | B2 |
| 7968752 | Lee et al. | Jun 2011 | B2 |
| 8039450 | Akama et al. | Oct 2011 | B2 |
| 8039451 | Baker et al. | Oct 2011 | B2 |
| 8106031 | Lee et al. | Jan 2012 | B2 |
| 8110259 | Siegel | Feb 2012 | B2 |
| 8115026 | Baker et al. | Feb 2012 | B2 |
| 8168614 | Baker et al. | May 2012 | B2 |
| 8343944 | Xia et al. | Jan 2013 | B2 |
| 8436028 | Hunt et al. | May 2013 | B2 |
| 8440642 | Baker et al. | May 2013 | B2 |
| 8461134 | Hernandez et al. | Jun 2013 | B2 |
| 8461135 | Akama et al. | Jun 2013 | B2 |
| 8461336 | Zhou et al. | Jun 2013 | B2 |
| 8461364 | Wheeler et al. | Jun 2013 | B2 |
| 8470803 | Akama et al. | Jun 2013 | B2 |
| 8501712 | Baker et al. | Aug 2013 | B2 |
| 8546357 | Akama et al. | Oct 2013 | B2 |
| 8669207 | Jacobson et al. | Mar 2014 | B1 |
| 8791258 | Chang et al. | Jul 2014 | B2 |
| 8906848 | Wuts et al. | Dec 2014 | B2 |
| 9138001 | Maclean et al. | Sep 2015 | B2 |
| 9138002 | Jacobson et al. | Sep 2015 | B2 |
| 9145429 | Jarnagin et al. | Sep 2015 | B2 |
| 9185914 | Frackenpohl et al. | Nov 2015 | B2 |
| 9309508 | Benkovic et al. | Apr 2016 | B2 |
| 9346834 | Zhou et al. | May 2016 | B2 |
| 9426996 | Maclean et al. | Aug 2016 | B2 |
| 9493489 | Jacobs et al. | Nov 2016 | B2 |
| 9493490 | Akama et al. | Nov 2016 | B1 |
| 9512148 | Chellappan et al. | Dec 2016 | B2 |
| 9572823 | Baker et al. | Feb 2017 | B2 |
| 9585396 | Malefyt et al. | Mar 2017 | B2 |
| 9617285 | Akama et al. | Apr 2017 | B2 |
| 9676796 | Kim et al. | Jun 2017 | B2 |
| 9730454 | Jacobson | Aug 2017 | B2 |
| 9737075 | Benkovic et al. | Aug 2017 | B2 |
| 9889146 | Alley et al. | Feb 2018 | B2 |
| 9944660 | Soni et al. | Apr 2018 | B2 |
| 10011616 | Zhang et al. | Jul 2018 | B2 |
| 10040806 | Rajan et al. | Aug 2018 | B2 |
| 10051864 | Stoller et al. | Aug 2018 | B2 |
| 10070649 | Malefyt et al. | Sep 2018 | B2 |
| 10159252 | Jacobson et al. | Dec 2018 | B2 |
| 20040259842 | Mikoshiba et al. | Dec 2004 | A1 |
| 20070155699 | Baker et al. | Jul 2007 | A1 |
| 20070286822 | Sanders et al. | Dec 2007 | A1 |
| 20070293457 | Baker et al. | Dec 2007 | A1 |
| 20080153992 | Knott et al. | Jun 2008 | A1 |
| 20080293675 | Lee et al. | Nov 2008 | A1 |
| 20080317737 | Patel et al. | Dec 2008 | A1 |
| 20090148623 | Sandmeier | Jun 2009 | A1 |
| 20090170861 | Aslanian et al. | Jul 2009 | A1 |
| 20090227541 | Baker et al. | Sep 2009 | A1 |
| 20090239824 | Lee et al. | Sep 2009 | A1 |
| 20090291917 | Akama et al. | Nov 2009 | A1 |
| 20100004205 | Mayer | Jan 2010 | A1 |
| 20100158992 | Black et al. | Jun 2010 | A1 |
| 20100190748 | Baker et al. | Jul 2010 | A1 |
| 20100256092 | Xia | Oct 2010 | A1 |
| 20100267981 | Baker et al. | Oct 2010 | A1 |
| 20100292504 | Baker et al. | Nov 2010 | A1 |
| 20110059985 | Schmidts et al. | Mar 2011 | A1 |
| 20110076261 | Patel et al. | Mar 2011 | A1 |
| 20110082118 | Patel et al. | Apr 2011 | A1 |
| 20110123624 | Zasloff | May 2011 | A1 |
| 20110124597 | Hernandez et al. | May 2011 | A1 |
| 20110136763 | Xia et al. | Jun 2011 | A1 |
| 20110152217 | Wheeler et al. | Jun 2011 | A1 |
| 20110166103 | Akama et al. | Jul 2011 | A1 |
| 20110166104 | Zhou et al. | Jul 2011 | A1 |
| 20110172187 | Hernandez et al. | Jul 2011 | A1 |
| 20110183969 | Birch | Jul 2011 | A1 |
| 20110190235 | Chen et al. | Aug 2011 | A1 |
| 20110207701 | Zhou et al. | Aug 2011 | A1 |
| 20110207702 | Jacobs et al. | Aug 2011 | A1 |
| 20110212918 | Hernandez et al. | Sep 2011 | A1 |
| 20110319361 | Baker et al. | Dec 2011 | A1 |
| 20120035132 | Jarnagin et al. | Feb 2012 | A1 |
| 20120115813 | Hernandez et al. | May 2012 | A1 |
| 20120214765 | Akama et al. | Aug 2012 | A1 |
| 20120264714 | Baker et al. | Oct 2012 | A1 |
| 20120289686 | Baker et al. | Nov 2012 | A1 |
| 20120295875 | Zhou et al. | Nov 2012 | A1 |
| 20130059802 | Baker et al. | Mar 2013 | A1 |
| 20130059803 | Baker et al. | Mar 2013 | A1 |
| 20130064783 | Baker et al. | Mar 2013 | A1 |
| 20130131016 | Akama et al. | May 2013 | A1 |
| 20130131017 | Akama et al. | May 2013 | A1 |
| 20130165411 | Gordeev et al. | Jun 2013 | A1 |
| 20130196433 | Raines et al. | Aug 2013 | A1 |
| 20130210770 | Baker et al. | Aug 2013 | A1 |
| 20130231304 | Jacobs et al. | Sep 2013 | A1 |
| 20130244980 | Baker et al. | Sep 2013 | A1 |
| 20130298290 | Haas | Nov 2013 | A1 |
| 20130316979 | Baker et al. | Nov 2013 | A1 |
| 20140088041 | Koop | Mar 2014 | A1 |
| 20140155305 | Hartshorne et al. | Jun 2014 | A1 |
| 20140259230 | Bobbio et al. | Sep 2014 | A1 |
| 20140349853 | Maclean et al. | Nov 2014 | A1 |
| 20150202321 | Alam | Jul 2015 | A1 |
| 20160199351 | Rappleye | Jul 2016 | A1 |
| 20160324160 | Benkovic | Nov 2016 | A1 |
| 20160340369 | Chen et al. | Nov 2016 | A1 |
| 20170000132 | Rajan et al. | Jan 2017 | A1 |
| 20170000133 | Rajan et al. | Jan 2017 | A1 |
| 20170037258 | Benkovic et al. | Feb 2017 | A1 |
| 20170042966 | Van der Weerden et al. | Feb 2017 | A1 |
| 20170280724 | Jacobson et al. | Jun 2017 | A1 |
| 20170216327 | Coronado et al. | Aug 2017 | A1 |
| 20170295809 | Malefyt et al. | Oct 2017 | A1 |
| 20170319536 | Blaszczyk et al. | Nov 2017 | A1 |
| 20170327519 | Akama et al. | Nov 2017 | A1 |
| 20170340607 | Birch et al. | Nov 2017 | A1 |
| 20170355719 | Hernandez et al. | Dec 2017 | A1 |
| 20180000089 | Stierli et al. | Jan 2018 | A1 |
| 20180000090 | Rajan et al. | Jan 2018 | A1 |
| 20180009831 | Ravishanker | Jan 2018 | A1 |
| 20180016285 | Baker et al. | Jan 2018 | A1 |
| 20180065994 | Akama et al. | Mar 2018 | A1 |
| 20180139975 | Malefyt et al. | May 2018 | A1 |
| 20180179229 | Barbosa et al. | Jun 2018 | A1 |
| 20180179233 | Gamsey et al. | Jun 2018 | A1 |
| 20180201628 | James et al. | Jul 2018 | A1 |
| 20180213781 | Muehlebach et al. | Aug 2018 | A1 |
| 20180220654 | Jacobson et al. | Aug 2018 | A1 |
| 20180230169 | Ramanujachary | Aug 2018 | A1 |
| 20180244699 | Rajan et al. | Aug 2018 | A1 |
| Number | Date | Country |
|---|---|---|
| 2010203096 | Feb 2010 | AU |
| 2012327171 | Jun 2013 | AU |
| 2012327230 | Jul 2013 | AU |
| 2190155 | Dec 1995 | CA |
| 2635680 | Jul 2007 | CA |
| 2642583 | Aug 2007 | CA |
| 2680587 | Sep 2009 | CA |
| 101505603 | Aug 2009 | CN |
| 102012006458 | Sep 2013 | DE |
| 0765331 | Sep 2000 | EP |
| 1444981 | Aug 2004 | EP |
| 1980564 | Oct 2008 | EP |
| 1765360 | Nov 2009 | EP |
| 1765358 | Feb 2011 | EP |
| 2343304 | Jul 2011 | EP |
| 2564857 | Mar 2013 | EP |
| 961280 | Jun 1964 | GB |
| 1006336 | Jun 1965 | GB |
| 1396904 | Jun 1975 | GB |
| 1995031970 | Nov 1995 | WO |
| 199533754 | Dec 1995 | WO |
| 1998021945 | May 1998 | WO |
| 2005087742 | Sep 2005 | WO |
| 2006089067 | Aug 2006 | WO |
| 2006102604 | Sep 2006 | WO |
| 2007071632 | Jun 2007 | WO |
| 2007078340 | Jul 2007 | WO |
| 2007095638 | Aug 2007 | WO |
| 2007131072 | Nov 2007 | WO |
| 2007146965 | Dec 2007 | WO |
| 2008064345 | May 2008 | WO |
| 2008070257 | Jun 2008 | WO |
| 2008115385 | Sep 2008 | WO |
| 2008156798 | Dec 2008 | WO |
| 2008157726 | Dec 2008 | WO |
| 2009046098 | Apr 2009 | WO |
| 2009053741 | Apr 2009 | WO |
| 2009111676 | Sep 2009 | WO |
| 2009130481 | Oct 2009 | WO |
| 2009140309 | Nov 2009 | WO |
| 2009144473 | Dec 2009 | WO |
| 2010027975 | Mar 2010 | WO |
| 2010028005 | Mar 2010 | WO |
| 2010045503 | Apr 2010 | WO |
| 2010045505 | Apr 2010 | WO |
| 2010080558 | Jul 2010 | WO |
| 2010136475 | Dec 2010 | WO |
| 2011017125 | Feb 2011 | WO |
| 2011019612 | Feb 2011 | WO |
| 2011019616 | Feb 2011 | WO |
| 2011019618 | Feb 2011 | WO |
| 2011022337 | Feb 2011 | WO |
| 2011037731 | Mar 2011 | WO |
| 2011043817 | Apr 2011 | WO |
| 2011049971 | Apr 2011 | WO |
| 2011060196 | May 2011 | WO |
| 2011060199 | May 2011 | WO |
| 2011063293 | May 2011 | WO |
| 2011094450 | Aug 2011 | WO |
| 2011116348 | Sep 2011 | WO |
| 2011150190 | Dec 2011 | WO |
| 2012033858 | Mar 2012 | WO |
| 2012067663 | May 2012 | WO |
| 2012069652 | May 2012 | WO |
| 2012139134 | Oct 2012 | WO |
| 2012154213 | Nov 2012 | WO |
| 2013033270 | Mar 2013 | WO |
| 2013050591 | Apr 2013 | WO |
| 2013057740 | Apr 2013 | WO |
| 2013058824 | Apr 2013 | WO |
| 2013078070 | May 2013 | WO |
| 2013078071 | May 2013 | WO |
| 2013093615 | Jun 2013 | WO |
| 2013108024 | Jul 2013 | WO |
| 2013110005 | Jul 2013 | WO |
| 2013154759 | Oct 2013 | WO |
| 2015097237 | Feb 2015 | WO |
| 2015175157 | Nov 2015 | WO |
| 2016015094 | Feb 2016 | WO |
| 2016151293 | Sep 2016 | WO |
| 2017102565 | Jun 2017 | WO |
| 2007079119 | Jul 2017 | WO |
| 2017125835 | Jul 2017 | WO |
| 2017136930 | Aug 2017 | WO |
| 2017180695 | Oct 2017 | WO |
| 2017183043 | Oct 2017 | WO |
| 2017207358 | Dec 2017 | WO |
| 2017216191 | Dec 2017 | WO |
| 2017216722 | Dec 2017 | WO |
| 2018060140 | Apr 2018 | WO |
| 2018102261 | Jun 2018 | WO |
| 2018156554 | Aug 2018 | WO |
| 2018160845 | Sep 2018 | WO |
| Entry |
|---|
| Baker, et al., (2006). “Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis.” Journal of Medicinal Chemistry 49(15): 4447-4450. |
| Rock, et al., (2007). “An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site.” Science 316(5832): 1759-1761. |
| International Search Report and Written Opinion, International Application No. PCT/US2017/020940, dated May 23, 2017, 7 pages. |
| Dauthy “Fruit and vegetable processing: Chapter 5.3 Chemical Preservation” FAO Agricultural Services Bulletin, 1995, No. 119. |
| Reddy et al., “1-MCP, a novel plant growth regulator for regulation of ripening” Agricultural & Horticultural Sciences, 2014, vol. 2. |
| Kumar, J.S. et al., “Development of Practical Methodologies for the Synthesis of Functionalized Benzoboroxoles”, Tetrahendron Letters, Elsevier, Amsterdam, NL, Col. 51, No. 34, Aug. 24, 2010, pp. 4482-4485. |
| Mao, W., “AN2690, a topical antifungal agent in development for the treatment of onychmycosis represents a new class and has a novel mechanism of action”, Anacor Pharmaceuticals AG, Aug. 20, 2008, XP007921849, www.anacor.com/pdf/SID_p769.pdf [retrieved on Jul. 11, 2013]. XP007921849, wwww. |
| Ding et al., “Design, Synthesis, and Structure—Activity Relationship of Trypanosoma brucei Leucyl-tRNA Synthetase Inhibitors as Antitrypanosomal Agents,” J. Med. Chem. (2011), vol. 54(5), pp. 1276-1287. |
| Alexander et al., “Imprinted Polymers as Protecting Groups for Regioselective Modification of Polyfunctional Substrates”, Journal of American Chemical Society, 1999, pp. 6640-6651, vol. 121, United Kingdom (12 pages). |
| Haynes et al., “Arylboronic Acids. Villl. Reactions of Boronophthalide”, Noyes Chemical Laboratory, University of Illinois, Nov. 1964, pp. 3229-3233 Urbana, USA (5 pages). |
| Brown et al., “Convenient Procedures for the Preparation of Alkyl Borate Esters,” Proc. For Prepn. Alkyl Borate Esters, Aug. 5, 1956, pp. 3613-3614. |
| Shen et al., “Changes of respiration and ethylene production and effects of 1-MCP during the fermentation softening of chinese winter jujube fruit,” Zhongguo Nongye Daxue Xuebao (2004) vol. 9(2), pp. 36-39. |
| Guillen et al., “Efficacy of 1-MCP treatment in tomato fruit 2. Effect of cultivar and ripening stage at harvest,” Postharvest Biology and Technol. (2006) vol. 42(3), pp. 235-242. |
| Carillo et al., “1-Methylcyclopropene delays arazá ripening and improves postharvest fruit quality,” LWT-Food Sci. and Tech. (2011) vol. 44, pp. 250-255. |
| Brown et al., “Convenient Procedures for the Preparation of Alkyl Borate Esters,” Procedures for Preparation of Alkyl Borate Esters, contribution from the Department of Chemistry of Purdue University, Aug. 5, 1956, 3613-3614. |
| Pubchem entry for AN2718 (https://pubchem.ncbi.nlm.nih.gov/compound/11845944) accessed Mar. 1, 2020. |
| Seiradake E, et al., “Antifungal activity and mechanism of action of a benzoxaborole, AN2718, which is in development for the treatment of Tinea pedis,” Abstract F1-1176, IDSA Poster Session: New Anti-Fungal Agents (2008). |
| Mao W, et al., “AN2718 has broad spectrum antifungal activity necessary for the topical treatment of skin and nail fungal infections,” Abstract P2422, J. American Acad. Dermatology 60(3) Supplement 1, AB116 (2009). |
| Rolshausen PE, et al., “Use of boron for the control of Eutypa dieback of grapevines,” Plant Diseases 89(7): 734-738 (2005). |
| Qin G, et al., “Inhibitory effect of boron against Botrytis cinerea on table grapes and its possible mechanisms of action,” International Journal of Food Microbiology 138: 145-150 (2010). |
| Thomidis T and Exadaktylou E., “Effect of boron on the development of brown rot (Monilinia laxa) on peaches,” Crop Prot. 29: 572-576 (2010). |
| Expert Declaration of Phillip M. Brannen, Ph.D., filed in an Inter Partes Review of U.S. Pat. No. 10,130,096, filed Nov. 5, 2019. |
| Boric Acid, Chemical Watch Factsheet, 21, 18-19 (2001). |
| Ligon JM, et al, “Natural products with antifungal activity from Pseudomonas biocontrol bacteria,” Pest Management Science 56: 688-695 (2000). |
| Alumni Product Registration (Jun. 9, 2010). |
| Propi-Shield Product Registration (Aug. 11, 2005). |
| Tilt Label (2006). |
| Mahmoud Yag, et al., “Recent approaches for controlling brown spot disease of faba bean in Egypt,” Egypt Acad. J. Biol. Sci. 3: 41-53 (2011). |
| Ware G, “Substituted aromatics,” pp. 148-149, In: Fundamentals of Pesticides: a self-instruction guide, Tomson Publications, Fresno, CA (1991). |
| Bertelsen Jr, et al., “Fungicidal effects of azoxystrobin and epoxiconazole on phyllosphere fungi, senescence and yield of winter wheat,” Plant Pathology 50: 190-205 (2001). |
| Propi-Shield Label Amendment (Nov. 29, 2006). |
| Azotech Label Amendment (Sep. 7, 2007). |
| PptiSHIELD Label (2009). |
| Abound label (2007). |
| Chlorosel label (2010). |
| Ultrex label (2005). |
| Chloroneb Fact Sheet (2005). |
| Dichloran Label Amendment (Aug. 5, 2010). |
| Expert Declaration of Dennis Hall, Ph.D. filed in an Inter Partes Review of U.S. Pat. No. 10,130,096, filed Nov. 5, 2019. |
| Patent Owner Preliminary Response filed in an Inter Partes Review of U.S. Pat. No. 10,130,096, filed Feb. 18, 2020. |
| Dictionary Reference filed in an Inter Partes Review of U.S. Pat. No. 10,130,096. |
| Petition for Inter Partes Review of U.S. Pat. No. 10,130,096, filed Nov. 5, 2019. |
| Marsh et al., J. Good Sc. 2007, vol. 72, R39-R54. |
| Edwards, “Organoboron reagents and recent strategies in rhodium catalysed additions,” Ph. D. Thesis submitted to University of Bath, 2011, pp. 1-293. |
| Ma, X. et al.,“Synthesis of Boroxine-Linked Aluminium Complexes,” Inorg. Chem., 2011, 50, 2010-2014. |
| Greig, L. et al., “The dynamic covalent chemistry of mono- and bifunctional boroxoaromatics”, Tetrahedron, 2006, 63, 2391-2403. |
| Weike, Z. et al.,“Preparation of 2-oxygen derivatives of 1,2-oxaborolane from 2-allyloxy-1,2-oxaborolane,” Journal of Organometallic Chemistry, 1990, 387, 131-146. |
| Office Action for Japanese Patent Application No. 2016-517975, dated Dec. 24, 2019, 4 pages. |
| International Search Report for PCT/US2014/013510, Dow AgroSciences LLC, dated Jun. 25, 2014. |
| “Smart Fog ES-100 models Installation and Operation Manual”, Jan. 1, 2012 (Jan. 1, 2012), pp. 1-30, KP0557247260, U.S.A., Retrieved from the Internet: URL:https://smartfog.com/pdf/mn_es100.pfd (retrieved on Aug. 24, 2020). |
| Number | Date | Country | |
|---|---|---|---|
| 20170251673 A1 | Sep 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62304636 | Mar 2016 | US |
